Effective chemotherapy for melanoma after treatment with interleukin‐2 Academic Article Article uri icon


MeSH Major

  • Cysts
  • Intervertebral Disc Degeneration
  • Intervertebral Disc Displacement
  • Radiography, Interventional
  • Steroids


  • Twenty patients with biopsy-proven metastatic malignant melanoma, previously treated with interleukin-2 (IL-2), received combination chemotherapy for progressive disease. Treatment included carmustine, cisplatin, dacarbazine, and tamoxifen (BCDT). Nausea was the most common toxicity (100%) and usually was mild. Persistent thrombocytopenia was the most frequent toxicity limiting further treatment. Eleven patients (55%) had an objective partial response, three patients (15%) had a minor response, and six patients (30%) had no change or progressive disease in response to this treatment. These results were comparable to the high response rates (21 of 40, 53%) achieved with BCDT in previously untreated patients with melanoma. It was concluded that prior therapy using IL-2 does not significantly alter the response rate of metastatic melanoma to BCDT, thus suggesting that immunomodulators (e.g., IL-2) and chemotherapeutic agents are not cross-resistant treatments.

publication date

  • January 1992



  • Academic Article


Digital Object Identifier (DOI)

  • 10.1002/1097-0142(19920115)69:2<427::AID-CNCR2820690225>3.0.CO;2-0

PubMed ID

  • 1728371

Additional Document Info

start page

  • 427

end page

  • 9


  • 69


  • 2